Clinical trials for professionals
Learn about our available clinical trials



-
September 18, 2023MadridIn recruitment
ASND0029 Clinical trial to investigate safety and tolerability of TransCon IL-2 in adult participants with malignant solid tumors
The objective of this research is to learn about the effects of an experimental drug called TransCon IL-2 ß/? when administered alone or in combination with pembrolizumab, chemotherapy ET or TransCon TLR7/8 agonist, or in combination with pembrolizumab and chemotherapy ET. -
September 6, 2023PamplonaIn recruitment
BGB-11417-101 Clinical trial of the Bcl-2 inhibitor BGB-11417 in patients with mature B-lymphocyte malignancies.
The objective of this trial is to determine safety and tolerability; to define the maximum tolerated dose (MTD) and recommended dose for Phase II (DRF2); and to evaluate the safety and tolerability of the step-up dosing schedule and DRF2 of BGB-11417, in monotherapy and in combination with zanubrutinib. -
August 23, 2023MadridIn recruitment
-
August 22, 2023PamplonaIn recruitment
IM048-022 Clinical trial to compare iberdomide maintenance therapy versus lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (MMND).
The purpose of this study is to better understand how an investigational drug called iberdomide (also known as BMS-986382 or CC-220) works to treat multiple myeloma, compared to lenalidomide (also known as Revlimid®), after you have undergone an autologous stem cell transplant (ASCT) and recovered, and your doctor feels it is appropriate to continue treatment to keep your myeloma under control. This is also called maintenance treatment. -
August 22, 2023MadridIn recruitment
IMC-F106C-101 Primer estudio en el ser humano de fase 1/2 sobre la seguridad y eficacia de IMC-F106C en monoterapia.
The main goal of this study is to find the highest dose of BMI-F106C that is safe to give to people with advanced cancer, and to find out if this dose can make tumors stop growing (or shrink) and if cancer patients can live longer and feel better. -
August 16, 2023PamplonaIn recruitment
BP43437 Trial of treatment combinations with forimtamig in participants with relapsed or refractory multiple myeloma.
The purpose of this study is to determine the effects (good or bad) of the following: -Forimtamig administered alone, compared to -Forimtamig administered together with carfilzomib, compared to -Forimtamig administered together with daratumumab. -
August 16, 2023PamplonaIn recruitment
CUN-PETNeuroTau Clinical trial to assess cerebral 4R Tau deposition by brain PET with 18F-PI2620 in progressive supranuclear palsy compared to controls without 4R neurodegenerative tauopathy
The purpose of the study is to collect clinical, brain imaging and neuropsychological data from patients with progressive supranuclear palsy or Parkinson's disease in order to analyze them, compare them with controls and draw conclusions about the pathological process involved in the cognitive, motor and psychiatric deficits of these diseases and thus advance their diagnosis and treatment. The results are of research interest only and for that reason you will be informed of the results only ... -
August 8, 2023PamplonaIn recruitment
1463-0001 Clinical trial of BI 765179 and ezabenlimab in patients with advanced cancer
The purpose of this study is to determine the appropriate dose of BI 765179 when administered alone and when administered in combination with ezabenlimab in patients with advanced cancer. This is the first time BI 765179 will be administered to humans. BI 765179 is an investigational drug that may treat cancer by interacting with the immune system. The immune system is the body's natural defense. The immune system sends cells called T-lymphocytes throughout the body to detect and fight infec... -
August 8, 2023PamplonaIn recruitment
TIG-006 Clinical trial of EOS884448 in combination with standard treatment and/or experimental therapies in participants with advanced solid tumors
The main objective of part 1G is to evaluate how well your body tolerates the study treatment (EOS-448 dostarlimab chemotherapy) and the efficacy of the study treatment on your tumor. The main objective of parts 2C and 2D is to evaluate the efficacy of the study treatment on your tumor and how well your body tolerates the study treatment (EOS-448 dostarlimab). The main objective of part 2E is to evaluate the efficacy of the study treatment on your tumor and how well your body tolerates the study... -
August 8, 2023PamplonaIn recruitment
GFH925X0201 Clinical trial of GFH925 in combination with cetuximab in patients with previously untreated advanced stage KRAS G12C mutated NSCLC
The objective of this study is to examine an investigational drug, GFH925, when used in combination with an antineoplastic called "cetuximab", in people with a particular type of NSCLC, called "NSCLC with KRAS G12C mutation". The KRAS G12C mutation is a type of mutation of a group of genes that control cell growth and division. Genes are segments of deoxyribonucleic acid (DNA), which is present in most cells. Genes decide the function and actions of the cell. When mutated, th...